657 related articles for article (PubMed ID: 19381089)
21. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
Hohman TC
Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
[TBL] [Abstract][Full Text] [Related]
22. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy for age-related macular degeneration.
Patel S
Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
[TBL] [Abstract][Full Text] [Related]
24. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
[TBL] [Abstract][Full Text] [Related]
25. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
Grisanti S; Tatar O
Prog Retin Eye Res; 2008 Jul; 27(4):372-90. PubMed ID: 18621565
[TBL] [Abstract][Full Text] [Related]
26. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
27. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
[TBL] [Abstract][Full Text] [Related]
28. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor and diabetic complications.
Wirostko B; Wong TY; Simó R
Prog Retin Eye Res; 2008 Nov; 27(6):608-21. PubMed ID: 18929676
[TBL] [Abstract][Full Text] [Related]
30. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
31. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
32. Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development.
Amadio M; Govoni S; Pascale A
Pharmacol Res; 2016 Jan; 103():253-69. PubMed ID: 26678602
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
34. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
36. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
Crawford Y; Ferrara N
Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
[TBL] [Abstract][Full Text] [Related]
37. [Surgical session: neovascular glaucoma and anti-vascular endothelial growth factor treatment].
Laplace O
J Fr Ophtalmol; 2009 Mar; 32(3):230-5. PubMed ID: 19515340
[TBL] [Abstract][Full Text] [Related]
38. Technology evaluation: pegaptanib, Eyetech/Pfizer.
Vinores SA
Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
[TBL] [Abstract][Full Text] [Related]
39. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.
Hosseini H; Nejabat M
Med Hypotheses; 2007; 68(4):799-801. PubMed ID: 17107753
[TBL] [Abstract][Full Text] [Related]
40. [Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?].
Ziemssen F; Gelisken F
Klin Monbl Augenheilkd; 2009 Jan; 226(1):31-7. PubMed ID: 19173161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
